Myelodysplastic Syndrome
Video
Heme Themes: Transplant timing for myelofibrosis in the era of JAK2 inhibitors
Video
Heme Themes: Challenges in averting the progression of MPN, MDS
News
Imetelstat elicits response in myelofibrosis, thrombocythemia
Key clinical point: The telomerase inhibitor imetelstat showed promise in separate preliminary studies for treatment of myelofibrosis and...
News
New HMA shows early promise for MDS/AML
Image by Christoph Bock Investigators say a novel hypomethylating agent (HMA) is safe and clinically active in patients with myelodysplastic...
News
Lenalidomide can treat pulmonary sarcoidosis in MDS
Treatment with lenalidomide can have a significant effect on pulmonary sarcoidosis in myelodysplastic syndrome (MDS), according to a case study....
News
Inhibitor could treat range of hematologic disorders
A small molecule that targets the sonic Hedgehog signaling pathway has advanced to phase 2 trials in a range of hematologic disorders. In a phase...
News
Genetic mutation identifies favorable prognosis MDS
Mutations in SF3B1 identify a subset of patients with MDS with favorable prognosis.
News
Clonal hematopoiesis explored in aplastic anemia
Key clinical point: Clonal hematopoiesis was detected in 47% of 439 patients with aplastic anemia, and some of the mutations were related to...
News
CD8 cell dose predicts outcomes in allogeneic stem cell transplantation with reduced-intensity conditioning
Key clinical point: High CD8 cell dose in peripheral blood stem cell grafts was associated with reduced risk of relapse and increased survival in...
News
ASCO: PERSIST-1 – pacritinib tops best available therapy in myelofibrosis
Key clinical point: Pacritinib is superior to best available therapy for alleviating splenomegaly and other symptoms of myelofibrosis. Major...
News
Dexrazoxane Tx did not affect overall survival in pediatric leukemia and lymphoma
Key clinical point: Treatment with dexrazoxane was not associated with an increased risk for cancer relapse or death. Major finding: For pediatric...